Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.
BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 ...
Envista Holdings Corporation ("Envista") today announced that the company will participate in a fireside chat at the Evercore HealthCONx Conference on Tuesday, December 3, 2024 from 12:30 ? 1:15 pm ET ...
Optic complications among hospitalized patients with RA, SLE, and SpA were linked to poor outcomes and higher health care costs, especially among Black and Asian patients.